Core Insights - Zentalis Pharmaceuticals is advancing the late-stage development of its first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment for ovarian cancer [1][3] - The management team will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11 in New York [1] Company Overview - Zentalis Pharmaceuticals focuses on developing innovative oncology treatments, particularly for ovarian cancer and various tumor types [3] - The company aims to provide a targeted, non-chemotherapy, orally available medicine that enhances treatment experience and outcomes for cancer patients [3] Event Information - A live webcast of the upcoming event will be available for at least 30 days after the event concludes, accessible under the "Events & Presentations" tab on the company's website [2]

Medicines Made for Life Nasdaq: AYTU February 2026 Actor portrayals. Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the futu ...

Core Viewpoint - Merck & Co., Inc. reported fourth-quarter results that met earnings expectations and slightly exceeded revenue forecasts, leading to a more than 2% increase in share price intraday [1] Group 1: Financial Performance - The company posted adjusted earnings per share of $2.04, aligning with analyst estimates [1] - Revenue increased by 5% year over year to $16.4 billion, surpassing the consensus estimate of $16.18 billion [1] Group 2: Growth Drivers - Growth was primarily driven by strong performance in oncology and animal health, along with contributions from newer products [2] - KEYTRUDA sales rose by 7% to $8.37 billion during the quarter [2] - Animal health revenue increased by 8% to $1.51 billion, supported by robust livestock demand [2] Group 3: Future Outlook - The 2026 outlook disappointed investors, with earnings forecasted at $5.00 to $5.15 per share, below analyst expectations of $5.63 [3] - A one-time charge of approximately $3.65 per share related to the acquisition of Cidara Therapeutics impacted the earnings forecast [3] - Revenue for 2026 is projected at $65.5 billion to $67.0 billion, slightly below the consensus of $67.58 billion [3] Group 4: Full-Year Sales - For the full year 2025, Merck reported worldwide sales of $65.0 billion, representing 1% growth, or 2% growth excluding foreign exchange [4] - KEYTRUDA generated $31.7 billion in annual sales [4] - Newer products WINREVAIR and CAPVAXIVE contributed $1.4 billion and $759 million, respectively [4]

Core Insights - Pfizer Inc. reported a decline in fourth-quarter revenue primarily due to reduced demand for COVID-19 products, although earnings exceeded analyst forecasts due to strong performance in vaccines and oncology [1][3] Revenue Performance - Operational revenue for the quarter ended December 31 decreased by 3% to $17.6 billion, surpassing Bloomberg consensus estimates of $16.94 billion [3] - Revenue from Pfizer's COVID-19 vaccine fell by 35% year over year, while sales of its antiviral COVID treatment dropped by 70%, attributed to lower infection rates and reduced utilization in the U.S. [1] Product Performance - Strong growth was observed in Abrysvo, Pfizer's respiratory syncytial virus vaccine for adults aged 18 to 59 at risk, with global sales increasing by 136% due to international demand and pricing [2] - Oncology biosimilars also showed significant growth, with sales rising by 76% year over year [2] Earnings and Guidance - Adjusted earnings per share for the quarter were reported at $0.66, exceeding expectations of $0.57 [3] - Pfizer reaffirmed its full-year guidance, projecting revenue between $59.5 billion and $62.5 billion and adjusted diluted EPS of $2.80 to $3.00 [3] Clinical Developments - Pfizer's experimental obesity treatment showed promising results, demonstrating up to 12.3% weight loss in non-diabetic patients during a mid-stage clinical trial [4]

Market Overview - Stocks declined on Tuesday, with the S&P 500 falling over 1% and the Nasdaq dropping approximately 2% due to a selloff in technology stocks [1] - Financial stocks, including Blue Owl Capital, KKR, Apollo Global Management, and BlackRock, also experienced declines as the market reacted to potential software losers from AI [1] Company-Specific Updates - Nvidia's stock fell more than 3% on Tuesday, maintaining a flat performance over the past six months; CEO Jensen Huang denied rumors of a fraying relationship with OpenAI during an interview with Jim Cramer [1] - Eli Lilly's shares dropped nearly 4% ahead of its earnings report, influenced by Novo Nordisk's disappointing guidance for 2026, which included a projected sales decline of 5% to 13% year over year [1] - Novo Nordisk's stock fell over 15% after announcing it expects lower sales in the U.S. due to price pressures and increasing competition, suggesting a potential loss of market share to Eli Lilly [1] Housing Market Insights - Housing-related stocks saw a rally following a report indicating efforts to make entry-level home buying more affordable, involving companies like Lennar and Taylor Morrison Home [1] - Despite the broader market decline, Home Depot's shares rose nearly 1%, indicating potential benefits from a revived housing market [1] Upcoming Earnings Reports - Key earnings reports expected after Tuesday's close include Advanced Micro Devices, Super Micro, Chipotle, Enphase Energy, Amgen, Amcor, Prudential Financial, Mondelez, and Corteva [1] - Notable reports before Wednesday's opening bell include GE Healthcare, Uber, Boston Scientific, Johnson Controls, AbbVie, Bunge, and Fortive [1]

Core Viewpoint - Johnson & Johnson (JNJ) is a leading player in the healthcare sector, demonstrating strong market performance and investor confidence, with RBC Capital maintaining an "Outperform" rating and raising the price target to $255 [1][4][5] Financial Performance - From May 2025 to February 2026, JNJ's stock increased by 52%, attributed to improved earnings and product achievements [2][5] - The company's revenue grew by 3.2%, supported by better margins, innovation, and strategic evolution [2] - JNJ's current stock price is $233.39, reflecting a 1.14% increase, with a daily trading range between $230.48 and $235.20 [2] Market Position - JNJ's market capitalization is approximately $562.31 billion, with a trading volume of 1,331,327 shares [3][5] - The stock has experienced a high of $235.24 and a low of $141.50 over the past year [3] Strategic Outlook - RBC Capital's decision to raise the price target indicates confidence in JNJ's future growth prospects, driven by strategic initiatives and product innovations [4][5] - The company's effective risk management and progress in legal matters have bolstered its positive performance and investor confidence [3]

It's been an interesting start to the year, with plenty of geopolitical developments for investors to unpack. The market managed monthly wins in January, but as we get into February, it's not a bad idea to keep an eye on stocks that have had a tendency to underperform. For your convenience, Schaeffer's Senior Quantitative Analyst Rocky White compiled a list of the 25 worst stocks on the S&P 500 over the last decade. Biogen Inc (NASDAQ:BIIB) is one of the worst stocks on the list. Per White, BIIB averages a ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class acti ...

Core Insights - Pfizer Inc. reported Q4 and full-year 2025 earnings, which were solid overall but missed estimates in certain areas, leading to a ~5% decline in shares during pre-market trading [1] Financial Performance - The earnings report indicated that while the overall performance was solid, specific metrics did not meet market expectations, prompting a negative reaction from investors [1] Market Reaction - The immediate selling pressure on Pfizer's shares was attributed to the earnings miss, reflecting investor sentiment and market dynamics following the announcement [1]

Core Viewpoint - Pfizer Inc. reported solid Q4 and full-year 2025 earnings, but missed estimates in some areas, leading to a ~5% decline in shares during pre-market trading [1] Financial Performance - The earnings report for Q4 and full-year 2025 was overall solid but did not meet all analyst expectations, resulting in a negative market reaction [1]